ATE425177T1 - Reduziertes fk228 und seine verwendung - Google Patents

Reduziertes fk228 und seine verwendung

Info

Publication number
ATE425177T1
ATE425177T1 AT01947940T AT01947940T ATE425177T1 AT E425177 T1 ATE425177 T1 AT E425177T1 AT 01947940 T AT01947940 T AT 01947940T AT 01947940 T AT01947940 T AT 01947940T AT E425177 T1 ATE425177 T1 AT E425177T1
Authority
AT
Austria
Prior art keywords
reduced
salt
compound
histone deacetylase
diseases
Prior art date
Application number
AT01947940T
Other languages
English (en)
Inventor
Hidenori Nakajima
Akito Tanaka
Minoru Yoshida
Sueharu Horinouchi
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Application granted granted Critical
Publication of ATE425177T1 publication Critical patent/ATE425177T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Materials For Medical Uses (AREA)
AT01947940T 2000-07-17 2001-07-09 Reduziertes fk228 und seine verwendung ATE425177T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000216584 2000-07-17

Publications (1)

Publication Number Publication Date
ATE425177T1 true ATE425177T1 (de) 2009-03-15

Family

ID=18711825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01947940T ATE425177T1 (de) 2000-07-17 2001-07-09 Reduziertes fk228 und seine verwendung

Country Status (7)

Country Link
US (1) US7056884B2 (de)
EP (1) EP1302476B1 (de)
JP (1) JP4810784B2 (de)
AT (1) ATE425177T1 (de)
DE (1) DE60137932D1 (de)
ES (1) ES2321584T3 (de)
WO (1) WO2002006307A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020817A1 (en) 2000-09-01 2002-03-14 Fujisawa Pharmaceutical Co., Ltd. A method of producing fr901228
PL210794B1 (pl) * 2001-08-21 2012-03-30 Astellas Pharma Inc Zastosowanie inhibitora deacetylazy histonowej FK228 lub jego soli
DE60331297D1 (de) 2002-03-07 2010-04-01 Univ Delaware Verfahren zur verstärkung der oligonucleotid-vermittelten nucleinsäuresequenzänderung unter verwendung von zusammensetzungen mit einem hydroxyharnstoff
MXPA04009761A (es) * 2002-04-05 2005-05-27 Fujisawa Pharmaceutical Co Dipsipeptido para terapia de cancer renal.
CA2495354A1 (en) * 2002-08-20 2004-03-04 Yamanouchi Pharmaceutical Co., Ltd. An agent for inhibiting articular cartilage extracellular matrix degradation
JPWO2004074478A1 (ja) * 2003-02-19 2006-06-01 アステラス製薬株式会社 ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
US7375228B2 (en) * 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP1491188A1 (de) * 2003-06-25 2004-12-29 G2M Cancer Drugs AG Topische Verwendung von Valproinsäure zur Behandlung von Hauterkrankungen
EP2238982B8 (de) * 2003-06-27 2013-01-16 Astellas Pharma Inc. Therapiemittel für Weichgewebesarkom
ES2425083T3 (es) 2003-09-25 2013-10-11 Astellas Pharma Inc. Agente antitumoral que comprende FK228 como inhibidor de histona desacetilasa y doxorrubicina como inhibidor de topoisomerasa II
EP1713460A2 (de) * 2003-12-10 2006-10-25 Wisconsin Alumni Research Foundation Fk228-analoga und ihre verwendung als hdac-hemmer
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
WO2006055621A2 (en) * 2004-11-17 2006-05-26 The University Of Chicago Histone deacetylase inhibitors and methods of use
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
CN101263121A (zh) * 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
EP1965824A4 (de) * 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc Metaboliten-derivate des hdac-inhibitors fk228
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
JP5178731B2 (ja) 2006-11-22 2013-04-10 カルス セラピューティクス リミテッド デプシペプチドおよびその治療的使用
CN101801994A (zh) * 2006-12-29 2010-08-11 格洛斯特制药公司 制备Romidepsin
BRPI0720734A2 (pt) * 2006-12-29 2014-01-07 Gloucester Pharmaceuticals Inc Preparação da romidepsina
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy
US20120190817A2 (en) 2010-07-12 2012-07-26 Celgene Corporation Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CA2874936A1 (en) * 2012-06-06 2013-12-12 Bionor Immuno As Vaccine
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
CN104450837B (zh) * 2013-09-18 2019-01-01 上海医药工业研究院 一种用于生产罗米地辛的方法及发酵培养基
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN109796521B (zh) * 2017-11-17 2022-04-19 上海医药工业研究院 一种罗米地辛醋酸盐晶型及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
ATE162850T1 (de) * 1993-09-10 1998-02-15 Kyowa Hakko Kogyo Kk Phospholipase c inhibitierendes peptid

Also Published As

Publication number Publication date
ES2321584T3 (es) 2009-06-09
DE60137932D1 (de) 2009-04-23
EP1302476A4 (de) 2006-06-28
JP4810784B2 (ja) 2011-11-09
EP1302476B1 (de) 2009-03-11
US7056884B2 (en) 2006-06-06
US20040053820A1 (en) 2004-03-18
WO2002006307A1 (fr) 2002-01-24
EP1302476A1 (de) 2003-04-16

Similar Documents

Publication Publication Date Title
DE60137932D1 (de) Reduziertes fk228 und seine verwendung
ATE388951T1 (de) Dpp-iv-inhibierende purin-derivative zur behandlung von diabetes
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
CA2336909A1 (en) Thiobenzimidazole derivatives which are useful as inhibitors of human chymase activity
HK1065258A1 (en) Benzothiazepine and benzothiadiazepine derivativeswith ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE303993T1 (de) 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
BR0212510A (pt) Inibidor de histona desacetilase, composto e composição
ATE399012T1 (de) Carbaminsäurederivate enthaltend eine piperazin verknüpfung als hdac-inhibitoren
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
CA2367017A1 (en) Inhibitors of impdh enzyme
HUP0401192A2 (hu) Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására
AU2002342878A1 (en) Pyridylpyrimidine derivatives as effective compounds against prion diseases
ATE448194T1 (de) Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
IL164767A0 (en) 7-Aryl-3,9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertenision, cardiovascular or renal diseases
NO20025810D0 (no) Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse
DE602004014791D1 (de) Zur behandlung von schmerzen geeignete phenylcarbonsäureamidverbindungen
TNSN04203A1 (en) Benzoxazinone-derived compounds, their preparation and use as medicaments
LV12291A (lv) Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai
IL123805A0 (en) Use of hydroximic acid derivatives for the protection of mitochondrial genome
BR0307588A (pt) Composto, inibidor de gsk-3, composição farmacêutica, e, agente terapêutico ou preventivo para uma doença
DE60211746D1 (de) Aminosäurederivate zur behandlung der alzheimer-krankheit
NO330964B1 (no) Kolkisosidanaloger
DE69400352D1 (de) 3- oder 4-Glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches Mittel

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1302476

Country of ref document: EP